ArticleHepatology international2014

Favorable adverse event profile of sofosbuvir/ribavirin compared to boceprevir/interferon/ribavirin for treatment of hepatitis C.

Shivakumar Narayanan et al.PubMed ↗Publisher ↗

No numbers read from the abstract.